Megan Adams to Support Founders with Complimentary Pitch Feedback at GITEX Europe
Volunteer Mentorship Sessions Led by Megan Adams at GITEX Europe Highlight Need for Founder Equity
'Strong ideas are everywhere, but access isn't. These sessions are one small way to help level the playing field and make sure more voices get heard.'— Megan Brittain Adams
BERLIN, GERMANY, May 14, 2025 / EINPresswire.com / -- As part of an ongoing commitment to mentoring early-stage entrepreneurs, Megan Brittain Adams will offer complimentary one-on-one pitch feedback sessions to startup founders attending GITEX Europe, taking place May 21–23, 2025, in Berlin.
Adams currently serves as Entrepreneur in Residence at Raha Beach Ventures, advising aspiring founders on strategy, storytelling, and team development. She also holds the role of Vice President of Strategic Partnerships & Outreach at Professional.me, a UAE-and-USA-based AI company specializing in ethical talent management.
Her participation in GITEX Europe follows Professional.me's recognition at the AI Everything Global Supernova Pitch Competition in Dubai, where the company was selected as one of the top AI startups worldwide.
The Berlin pitch feedback sessions are not part of a commercial program, but rather a volunteer initiative to give back to the startup community. Sessions will be focused on helping early-stage founders refine their core messaging, clarify their value proposition, and prepare for future conversations with investors and partners.
While the pitch feedback sessions are open to all early-stage founders, Adams notes that the barriers are often even steeper for women in the startup space. According to a 2023 report by PitchBook, female-only founding teams received just 2.1% of total venture capital funding globally—a number that has remained stubbornly low for years.
'Strong ideas are everywhere, but access isn't,' said Adams. 'These sessions are one small way to help level the playing field and make sure more voices get heard.'
Adams brings a non-traditional background to the startup ecosystem. She began her career in public relations, with award-winning education campaigns in collaboration with FEMA and the US Geological Survey in California. Later, she transitioned into clinical healthcare, graduating from the accelerated nursing program at Johns Hopkins University, one of the most competitive and prestigious programs of its kind.
Her work in the UAE includes serving as Chief Nursing Officer for a 250-person clinical team and co-founding a pediatric homecare startup that became the first in the region to receive CARF's highest level of international accreditation for quality of care.
In recent years, Adams has judged the regional rounds of the Hult Prize at Hult International Business School, mentored student-led ventures at the University of Dubai Pitch Competition, and developed the Raha Beach Ventures Internship Program, which has supported aspiring entrepreneurs from top global universities.
Appointments for the GITEX Europe sessions are limited and intended for early-stage founders seeking strategic guidance on pitch development.
Event Details:
📍 Messe Berlin, Germany
📅 May 21–23, 2025
📩 Inquiries and appointment requests: [email protected]
Megan Brittain Adams, VP Strategic Partnerships & Outreach
Professional.me
+1 302-405-3904
email us here
Visit us on social media:
LinkedIn
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
NHS faces paying more for US drugs to avoid future Trump tariffs
Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'
Bloomberg
39 minutes ago
- Bloomberg
Honeywell Open to Acquisitions in Europe as Defense Ramps Up
Honeywell is open to acquiring more companies in Europe to beef up its portfolio as the region ramps up its defense spending and military capabilities. The North Carolina-based company would consider partnerships and venture investment across Europe, Ben Driggs, Honeywell Aerospace Technologies Chief Commercial and Strategy Officer, said on Sunday. Navigation, safety systems and control systems around thermal management and electrification are among the areas which Honeywell would be interested to expand in, he said.
Yahoo
an hour ago
- Yahoo
Sober karaoke on the rise as Gen Z ditch booze
Young people who shun alcohol are driving a boom in 'sober karaoke', putting them at odds with older generations who typically only sing after a few drinks. Charlie Elek, chief executive of Britain's biggest chain of karaoke bars Lucky Voice, said he had seen an increase Gen Z eschewing booze during their singing sessions – breaking with the popular image of karaoke as a late night activity only undertaken when the pubs have shut. He said 8pm was now the most popular time for bookings, compared to 10pm 'back in the day', because of a shift in drinking culture. 'Back in the day we were very much about post-pub activity. People would feel the need to have five drinks before coming to Lucky Voice. With Gen Z not not drinking the same ways that we used to, that that has changed over time,' he said. He said that older people were still drinking more ahead of karaoke sessions. 'There's definitely some people who feel – it's an older generation – that, 'well, I'm not going to do karaoke until I have about five pints'. 'There's something kind of more guarded about the older generations.' It comes amid a broader shift away from traditional pubs in terms of where younger people socialise. While Britain's pub industry has suffered many closures in recent years, so-called 'competitive socialising' venues offering activities like karaoke, axe throwing and shuffleboard have become more popular. Younger people in particular are cutting down on alcohol – with many now going completely teetotal. In a survey by Kantar last year, 59pc of Gen Z – which are defined as people born in or after 1997 – claimed not to have drunk any alcohol in the last 12 months. Mr Elek said this meant the chain was having to cater to a 'different type of customer'. 'They do come earlier,' he said. 'We have had to work a lot on our low & no [alcohol] menu, and that's getting really big pick up.' Founded in 2005 by Martha Lane Fox, the Baroness of Soho and her business partners Julian Douglas and Nick Thistleton, Lucky Voice is Britain's biggest chain dedicated exclusively to karaoke. It runs five bars in London and one in Brighton. As drinking habits have changed, the chain has also begun taking more corporate bookings and hosting more parties for children. The business pulled in its best Christmas on record in 2024, with sales rising 17pc compared with the prior year. However, as well as seeing a rise in sober karaoke, Mr Elek said he had noticed some customers staying out later on Sundays and week nights because they are working from home and do not have to go into the office the next day. He said: 'There's just a slight different attitude from the days where everyone was working five days a week and you knew that you were going to be at desk at 8:30am.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
